Fig. 3.

Unlike Dex, a 3-mo treatment with CpdX, CpdX-D3, or any of their enantiomers does not lead to a loss of body weight, a change in body composition, or undesirable tissue-specific toxic side effects. (A) Change in body weight after a 3-mo treatment. (B) Fat percentage and (C) lean mass percentage for mice treated for 3 mo. The data correspond to the mean (as pointed out by arrow heads) ± SEM for, at least, nine mice per treatment. The statistical significance was calculated through the Krustal–Walis test followed by Dunn’s multiple comparison test; (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (ns): not significant. Weight (in grams) of thymus (D), spleen (E), kidney (F), and adrenal gland (G) in mice treated for 3 mo as indicated. Data are represented as mean ± SEM for, at least, nine mice per treatment. The statistical significance of the data, compared with vehicle treatment was calculated by Student t test; (*) P < 0.05; (***) P < 0.001.